MDT
★★★☆☆ WatchtemplateMedtronic plc
Healthcare · sector percentile 100
Session move
$87.09
Vol 2.92× avg
73/100 quant · tgt $104.83
RS60 +0.2% vs SPY · ADV$ 1579.1M
session 2026-10-06 · Snapshot — not live tape
Since last scan
2026-10-06 → 2026-10-07
Context only — not a buy/sell signal. Built from scan history and cached news/filings.
Snapshot quote
session 2026-10-06 · scan 2026-10-07 · pushed 10-07 13:12 ET · Regular session (stale)
Show quote fundamentalsHide quote fundamentals
- Last (scan/close)
- $87.27
- Previous close
- $87.97
- Pushed last
- $86.75 (stale) · 10-07 13:12 ET · Regular session
- Session open
- $87.97
- Last session range
- $86.45 – $88.50
- 52-week range
- $72.65 – $103.76
- Session volume
- 52,132,703
- Avg volume (20d)
- 17,825,020
- Market cap
- $111.63B
- PE (TTM)
- 21.44
- Forward PE
- 13.61
- Dividend yield
- 3.27%
- 1y target est.
- $104.83
- Next earnings
- 2026-11-17
Snapshot quote — last daily session bars and scan fundamentals. Not live bid/ask or intraday quotes.
If you put $1,000.00 in
1y ago
$907.60
−9%
5y ago
$809.14
−19%
Price path only from cached daily closes (adjusted when available). Not dividends cash, fees, or advice.
Market briefing
Curated digest — not a trade signal. Headlines and links as provided by the producer.
- Kevin Warsh's Inflation Stance Makes These Cheap Dividend Stocks Look a Lot More Attractive
Inflation is running hot, and the Fed is raising interest rates, but consumers aren't likely to pull back on the products these companies sell.
Yahoo · 2026-10-01
- Medtronic Receives Category I CPT® Code Approvals for Altaviva™ and Symplicity Spyral™ Systems
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the American Medical Association (AMA) approved new Category I Current Procedural Terminology (CPT®) codes for two of its technologies, which represent important long-term growth opportunities for Medtronic: Altaviva™ implantable tibial neuromodulation device for the treatment of urge urinary incontinence and Symplicity Spyral™ renal denervation (RDN) system for the treatment of uncontrolled hypertension. T
Yahoo · 2026-10-01
- Was The Run In JNJ Stock Hiding In Plain Sight?
Johnson & Johnson (JNJ) stock returned around 52% in the twelve months, against 17% for the S&P 500. A $10,000 holding became about $15,220. Over that period, J&J’s revenue growth accelerated even as the company navigated the anticipated loss of exclusivity and biosimilar erosion for STELARA. If that shift showed up in J&J's calls and filings first, a reader could have spotted it early. So was J&J's run in plain sight before it began.
Yahoo · 2026-09-30
Price Chart
Daily prices from cache
Loading price history…
AI Analysis
- Bull Thesis — MDT scores 73.15/100 (Watch) with revenue growth at 13.7% and a multi-factor profile supporting the current ranking.
- Risks — Key risks for MDT include valuation compression, sector rotation, and any deterioration in earnings momentum or balance-sheet leverage. Context: cached next earnings 2026-11-17.
- Target Upside — Consensus implied upside is 20.1%. Category 'Watch' suggests monitoring position sizing against the 100-point model thresholds.
Score History
30 days of scans. Daily batch adds the next weekday automatically while the API is running.
- DatePriceChgScoreRating
- 2026-10-07$87.27−$1.2173.2Watch
- 2026-10-06$88.48+$2.1074.0Watch
- 2026-10-05$86.38+$0.3669.4Pass
- 2026-10-02$86.02+$0.0972.3Watch
- 2026-10-01$85.93−$0.4772.0Watch
- 2026-09-30$86.41−$1.3474.4Watch
- 2026-09-29$87.75−$0.2175.6Watch
- 2026-09-28$87.96+$0.3174.0Watch
- 2026-09-25$87.65−$1.6573.6Watch
- 2026-09-24$89.30−$1.4773.7Watch
- 2026-09-23$90.77−$0.9869.2Pass
- 2026-09-22$91.75−$0.2368.9Pass
- 2026-09-21$91.98−$0.2676.2Watch
- 2026-09-18$92.24−$0.7676.4Watch
- 2026-09-17$93.00−$0.9277.2Watch
- 2026-09-16$93.93+$0.5675.4Watch
- 2026-09-15$93.37−$0.1775.8Watch
- 2026-09-14$93.53+$2.1275.9Watch
- 2026-09-11$91.41−$0.5075.4Watch
- 2026-09-10$91.91−$1.2575.7Watch
- 2026-09-09$93.16−$1.0174.8Watch
- 2026-09-08$94.17$0.0075.3Watch
- 2026-09-07$94.17+$1.0775.3Watch
- 2026-09-04$93.10+$0.9268.7Pass
- 2026-09-03$92.18+$0.1470.9Watch
- 2026-09-02$92.04+$1.3962.8Pass
- 2026-09-01$90.65−$0.5864.0Pass
- 2026-08-31$91.23+$1.2663.9Pass
- 2026-08-28$89.97−$2.0563.8Pass
- 2026-08-27$92.02—63.1Pass
Quant Breakdown
Short volume (FINRA)
Off-exchange short sale volume ratio vs recent sessions — not a squeeze forecast.
- Short / total
- 71.2%
- vs 20d (z)
- 1.75
- Short vol
- 13,093,691
- Status
- ok
Squeeze pressure score
full63/100
- Short leg
- 68
- Call leg
- 70
- Activity
- 10.0
- Call vol share
- 62.0%
- PCR (vol)
- 0.61
- Call OI share
- 68.1%
- ATM IV
- 48.3%
FINRA off-exchange short volume (TRF/ADF consolidated). Not short interest as % of float. Squeeze pressure score (0–100) — free composite of off-exchange short volume and (when available) call-side options activity. Not a probability that a squeeze will occur.
Disclosure score
Rule-based News / Insider / Earnings legs from cached SEC filings — context only, not beat/miss or a buy signal.
No recent SEC filings or earnings calendar inputs in the score window yet.
Disclosure event score — rule-based view of recent SEC filings and earnings calendar. Not a prediction that price will move, and not earnings beat/miss.
Earnings surprise (quant context)
From Yahoo/public fundamentals cached on the last quant scan — not part of the disclosure event score, and not a buy signal. Figure can lag the latest print.
Last reported surprise +0.4%
Filings & events
Recent SEC disclosures and earnings dates — context only, not a trade signal.
- Next earnings
- 2026-11-17yahoo_calendar
- Last earnings
- 2026-09-01yahoo_calendar
- SEC ↗8-K2026-09-17
8-K
- SEC ↗42026-09-17
FORM 4
- SEC ↗42026-09-16
FORM 4
- SEC ↗10-Q2026-09-03
10-Q
- SEC ↗8-K2026-09-01
8-K
- SEC ↗42026-08-24
FORM 4
- SEC ↗42026-08-04
FORM 4
- SEC ↗42026-08-04
FORM 4
- SEC ↗42026-08-04
FORM 4
- SEC ↗42026-08-04
FORM 4
SEC filings as reported; earnings dates may come from Yahoo calendar. Context only — not investment advice and not a prediction that price will move on a filing or event.